FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286009783> ?p ?o ?g. }

• W4286009783 endingPage "e071249" @default.
• W4286009783 startingPage "e071249" @default.
• W4286009783 abstract "Abstract Objective To estimate waning of covid-19 vaccine effectiveness over six months after second dose. Design Cohort study, approved by NHS England. Setting Linked primary care, hospital, and covid-19 records within the OpenSAFELY-TPP database. Participants Adults without previous SARS-CoV-2 infection were eligible, excluding care home residents and healthcare professionals. Exposures People who had received two doses of BNT162b2 or ChAdOx1 (administered during the national vaccine rollout) were compared with unvaccinated people during six consecutive comparison periods, each of four weeks. Main outcome measures Adjusted hazard ratios for covid-19 related hospital admission, covid-19 related death, positive SARS-CoV-2 test, and non-covid-19 related death comparing vaccinated with unvaccinated people. Waning vaccine effectiveness was quantified as ratios of adjusted hazard ratios per four week period, separately for subgroups aged ≥65 years, 18-64 years and clinically vulnerable, 40-64 years, and 18-39 years. Results 1 951 866 and 3 219 349 eligible adults received two doses of BNT162b2 and ChAdOx1, respectively, and 2 422 980 remained unvaccinated. Waning of vaccine effectiveness was estimated to be similar across outcomes and vaccine brands. In the ≥65 years subgroup, ratios of adjusted hazard ratios for covid-19 related hospital admission, covid-19 related death, and positive SARS-CoV-2 test ranged from 1.19 (95% confidence interval 1.14 to 1.24) to 1.34 (1.09 to 1.64) per four weeks. Despite waning vaccine effectiveness, rates of covid-19 related hospital admission and death were substantially lower among vaccinated than unvaccinated adults up to 26 weeks after the second dose, with estimated vaccine effectiveness ≥80% for BNT162b2, and ≥75% for ChAdOx1. By weeks 23-26, rates of positive SARS-CoV-2 test in vaccinated people were similar to or higher than in unvaccinated people (adjusted hazard ratios up to 1.72 (1.11 to 2.68) for BNT162b2 and 1.86 (1.79 to 1.93) for ChAdOx1). Conclusions The rate at which estimated vaccine effectiveness waned was consistent for covid-19 related hospital admission, covid-19 related death, and positive SARS-CoV-2 test and was similar across subgroups defined by age and clinical vulnerability. If sustained to outcomes of infection with the omicron variant and to booster vaccination, these findings will facilitate scheduling of booster vaccination." @default.
• W4286009783 created "2022-07-21" @default.
• W4286009783 creator A5000852141 @default.
• W4286009783 creator A5004896999 @default.
• W4286009783 creator A5006216908 @default.
• W4286009783 creator A5010056291 @default.
• W4286009783 creator A5011400484 @default.
• W4286009783 creator A5014136509 @default.
• W4286009783 creator A5018278249 @default.
• W4286009783 creator A5019321925 @default.
• W4286009783 creator A5020811770 @default.
• W4286009783 creator A5032044970 @default.
• W4286009783 creator A5032960366 @default.
• W4286009783 creator A5033301030 @default.
• W4286009783 creator A5035631466 @default.
• W4286009783 creator A5037645558 @default.
• W4286009783 creator A5037916338 @default.
• W4286009783 creator A5042952004 @default.
• W4286009783 creator A5043696036 @default.
• W4286009783 creator A5043858858 @default.
• W4286009783 creator A5045586161 @default.
• W4286009783 creator A5046267062 @default.
• W4286009783 creator A5047279233 @default.
• W4286009783 creator A5049699144 @default.
• W4286009783 creator A5054757405 @default.
• W4286009783 creator A5055949314 @default.
• W4286009783 creator A5061820843 @default.
• W4286009783 creator A5066907464 @default.
• W4286009783 creator A5072132922 @default.
• W4286009783 creator A5080417105 @default.
• W4286009783 creator A5089833703 @default.
• W4286009783 date "2022-07-20" @default.
• W4286009783 modified "2023-10-17" @default.
• W4286009783 title "Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records" @default.
• W4286009783 cites W2507826825 @default.
• W4286009783 cites W2509529180 @default.
• W4286009783 cites W3111255098 @default.
• W4286009783 cites W3111590711 @default.
• W4286009783 cites W3161135492 @default.
• W4286009783 cites W3166132123 @default.
• W4286009783 cites W3175808539 @default.
• W4286009783 cites W3184226105 @default.
• W4286009783 cites W3196352038 @default.
• W4286009783 cites W3198593250 @default.
• W4286009783 cites W3202826390 @default.
• W4286009783 cites W4200431335 @default.
• W4286009783 cites W4200598171 @default.
• W4286009783 cites W4205405695 @default.
• W4286009783 cites W4206935916 @default.
• W4286009783 cites W4207056100 @default.
• W4286009783 cites W4210301583 @default.
• W4286009783 cites W4220907252 @default.
• W4286009783 cites W4225470021 @default.
• W4286009783 cites W4225505755 @default.
• W4286009783 cites W4225854071 @default.
• W4286009783 cites W4226054307 @default.
• W4286009783 cites W4226090490 @default.
• W4286009783 cites W4226124668 @default.
• W4286009783 cites W4226240956 @default.
• W4286009783 cites W4226246286 @default.
• W4286009783 cites W4226376477 @default.
• W4286009783 cites W4285395899 @default.
• W4286009783 doi "https://doi.org/10.1136/bmj-2022-071249" @default.
• W4286009783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35858698" @default.
• W4286009783 hasPublicationYear "2022" @default.
• W4286009783 type Work @default.
• W4286009783 citedByCount "25" @default.
• W4286009783 countsByYear W42860097832022 @default.
• W4286009783 countsByYear W42860097832023 @default.
• W4286009783 crossrefType "journal-article" @default.
• W4286009783 hasAuthorship W4286009783A5000852141 @default.
• W4286009783 hasAuthorship W4286009783A5004896999 @default.
• W4286009783 hasAuthorship W4286009783A5006216908 @default.
• W4286009783 hasAuthorship W4286009783A5010056291 @default.
• W4286009783 hasAuthorship W4286009783A5011400484 @default.
• W4286009783 hasAuthorship W4286009783A5014136509 @default.
• W4286009783 hasAuthorship W4286009783A5018278249 @default.
• W4286009783 hasAuthorship W4286009783A5019321925 @default.
• W4286009783 hasAuthorship W4286009783A5020811770 @default.
• W4286009783 hasAuthorship W4286009783A5032044970 @default.
• W4286009783 hasAuthorship W4286009783A5032960366 @default.
• W4286009783 hasAuthorship W4286009783A5033301030 @default.
• W4286009783 hasAuthorship W4286009783A5035631466 @default.
• W4286009783 hasAuthorship W4286009783A5037645558 @default.
• W4286009783 hasAuthorship W4286009783A5037916338 @default.
• W4286009783 hasAuthorship W4286009783A5042952004 @default.
• W4286009783 hasAuthorship W4286009783A5043696036 @default.
• W4286009783 hasAuthorship W4286009783A5043858858 @default.
• W4286009783 hasAuthorship W4286009783A5045586161 @default.
• W4286009783 hasAuthorship W4286009783A5046267062 @default.
• W4286009783 hasAuthorship W4286009783A5047279233 @default.
• W4286009783 hasAuthorship W4286009783A5049699144 @default.
• W4286009783 hasAuthorship W4286009783A5054757405 @default.
• W4286009783 hasAuthorship W4286009783A5055949314 @default.
• W4286009783 hasAuthorship W4286009783A5061820843 @default.
• W4286009783 hasAuthorship W4286009783A5066907464 @default.
• W4286009783 hasAuthorship W4286009783A5072132922 @default.
• W4286009783 hasAuthorship W4286009783A5080417105 @default.

• next